ATE536179T1 - L-citrullin zur behandlung von erektiler dysfunktion - Google Patents
L-citrullin zur behandlung von erektiler dysfunktionInfo
- Publication number
- ATE536179T1 ATE536179T1 AT09728678T AT09728678T ATE536179T1 AT E536179 T1 ATE536179 T1 AT E536179T1 AT 09728678 T AT09728678 T AT 09728678T AT 09728678 T AT09728678 T AT 09728678T AT E536179 T1 ATE536179 T1 AT E536179T1
- Authority
- AT
- Austria
- Prior art keywords
- citrulline
- treatment
- erectile dysfunction
- dysfunction
- pycnogenol
- Prior art date
Links
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 title abstract 5
- 208000010228 Erectile Dysfunction Diseases 0.000 title abstract 2
- 201000001881 impotence Diseases 0.000 title abstract 2
- 229960002173 citrulline Drugs 0.000 abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
- 206010048554 Endothelial dysfunction Diseases 0.000 abstract 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 abstract 1
- 241000221013 Viscum album Species 0.000 abstract 1
- 239000006286 aqueous extract Substances 0.000 abstract 1
- 229920002770 condensed tannin Polymers 0.000 abstract 1
- 230000008694 endothelial dysfunction Effects 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 229960000304 folic acid Drugs 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000018192 pine bark supplement Nutrition 0.000 abstract 1
- 229940106796 pycnogenol Drugs 0.000 abstract 1
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 abstract 1
- 229960004617 sapropterin Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000567A ITMI20080567A1 (it) | 2008-04-02 | 2008-04-02 | L-citrullina per il trattamento della disfunzione endoteliale e della disfunzione erettile. |
PCT/EP2009/052799 WO2009121687A1 (en) | 2008-04-02 | 2009-03-10 | L-citrulline for treating endothelial dysfunction and erectile dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE536179T1 true ATE536179T1 (de) | 2011-12-15 |
Family
ID=40296835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT09728678T ATE536179T1 (de) | 2008-04-02 | 2009-03-10 | L-citrullin zur behandlung von erektiler dysfunktion |
Country Status (8)
Country | Link |
---|---|
US (1) | US8802162B2 (de) |
EP (1) | EP2257283B9 (de) |
AT (1) | ATE536179T1 (de) |
DK (1) | DK2257283T3 (de) |
ES (1) | ES2378656T3 (de) |
IT (1) | ITMI20080567A1 (de) |
PL (1) | PL2257283T3 (de) |
WO (1) | WO2009121687A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120093950A1 (en) * | 2010-10-19 | 2012-04-19 | Klrm, Llc | Compositions and methods for treating, inhibiting the onset, and slowing the progression of erectile dysfunction including naturally occuring age related erectile dysfunction |
US20150011463A1 (en) * | 2012-02-15 | 2015-01-08 | Kyowa Hakko Bio Co., Ltd. | Agent for preventing or ameliorating vascular endothelial malfunction |
US9572848B1 (en) | 2014-03-26 | 2017-02-21 | Aemes Research L.L.L.P. | Composition of matter for sexual dysfunction |
US10881686B2 (en) | 2017-10-27 | 2021-01-05 | Zeta Biolongevity, Inc | Compositions and methods for treating and preventing proteinuria and endothelial erosion |
WO2022027122A1 (en) * | 2020-08-06 | 2022-02-10 | Ramade & Cia Holding Corp. | Compositions with cannabinoids of cannabis sativa for treating erectile and sexual dysfunction |
US20220401396A1 (en) * | 2021-06-22 | 2022-12-22 | Asklepion Pharmaceuticals, Llc | Action of l-citrulline to prevent or treat endothelial dysfunction |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4341000A1 (de) | 1993-12-02 | 1995-06-08 | Beiersdorf Ag | Verwendung von L-Arginin, L-Ornithin oder L-Citrullin und topischen Zubereitungen mit diesen Stoffen |
WO2005107735A2 (en) | 2004-04-30 | 2005-11-17 | Pump Formulations, Ltd. | Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, incresing nutrient delivery and/or promoting increased vascular response in a |
WO2006002096A2 (en) | 2004-06-18 | 2006-01-05 | Vivo Therapeutics, Inc. | Low doses of l-citrulline for treating diseases |
US20090286802A1 (en) * | 2005-04-13 | 2009-11-19 | Ahmed Tawakol | High Dose Folic Acid Compositions for Vascular Dysfunction |
BRPI0710044A2 (pt) | 2006-04-04 | 2011-08-02 | Nestec Sa | tratamentos usando citrulina |
-
2008
- 2008-04-02 IT IT000567A patent/ITMI20080567A1/it unknown
-
2009
- 2009-03-10 US US12/935,782 patent/US8802162B2/en active Active
- 2009-03-10 DK DK09728678.5T patent/DK2257283T3/da active
- 2009-03-10 PL PL09728678T patent/PL2257283T3/pl unknown
- 2009-03-10 AT AT09728678T patent/ATE536179T1/de active
- 2009-03-10 ES ES09728678T patent/ES2378656T3/es active Active
- 2009-03-10 WO PCT/EP2009/052799 patent/WO2009121687A1/en active Application Filing
- 2009-03-10 EP EP09728678A patent/EP2257283B9/de active Active
Also Published As
Publication number | Publication date |
---|---|
ITMI20080567A1 (it) | 2009-10-03 |
PL2257283T3 (pl) | 2012-05-31 |
EP2257283B9 (de) | 2012-04-04 |
DK2257283T3 (da) | 2012-03-26 |
US8802162B2 (en) | 2014-08-12 |
EP2257283B1 (de) | 2011-12-07 |
EP2257283A1 (de) | 2010-12-08 |
US20110044965A1 (en) | 2011-02-24 |
WO2009121687A1 (en) | 2009-10-08 |
ES2378656T3 (es) | 2012-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE536179T1 (de) | L-citrullin zur behandlung von erektiler dysfunktion | |
UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
MEP59208A (en) | Activin-actriia antagonists and uses for promoting bone growth | |
CL2011000838A1 (es) | Compuestos heterociclicos derivados de tetraciclos ortocondensados con un grupo pirimidina 2,4,6-triona espirocondensado, inhibidores de la adn girasa bacteriana; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una infeccion bacteriana. | |
EA200802184A1 (ru) | Фармацевтические композиции с ингибиторами dpp iv | |
CL2007002640A1 (es) | Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2007002642A1 (es) | Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
MX2018000590A (es) | Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79). | |
EA201101117A1 (ru) | Ингибиторы дпп-4 для лечения диабета у детей | |
BR112013030166A2 (pt) | método de diferenciação de células haste pluripotentes em células leito vasculares, células endoteliais ou células dos músculos moles vasculares, banco biológico e uso de células endoteliais ou células dos músculos moles vasculares, composição terapêutica, métodos e usos. | |
CL2007002062A1 (es) | Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
CL2008001855A1 (es) | Compuestos ciclicos condensados derivados del boro; composicion farmaceutica; y uso en el tratamiento y/o prevencion de una enfermedad infecciosa. | |
HRP20110861T1 (hr) | Lijek za liječenje gripe | |
WO2010094009A3 (en) | Methods and compositions for the treatment of ras associated disorders | |
WO2008079460A3 (en) | Tyrosine kinase inhibitors for prevention or treatment of infection | |
MX2009009117A (es) | Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2. | |
SG170751A1 (en) | Extractions and methods comprising elder species | |
CL2009000119A1 (es) | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. | |
BRPI0922233A2 (pt) | compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas. | |
CL2007002671A1 (es) | Compuestos derivados de octahidro-pirrolo[3,4-c]pirrol; composicion farmaceutica que la comprende; y uso del compuesto en el tratamiento del vih, sida o arc. | |
CL2007003038A1 (es) | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. | |
CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. | |
CL2008003602A1 (es) | Compuestos derivados de triazolotriazinas y triazolopirazinas sustituidas; composicion farmaceutica; y su uso en el tratamiento y/o profilaxis de trastornos hematologicos. | |
NO20082838L (no) | 9-klor-15-deoksyprostaglandinderivater, fremgangsmate for fremstilling av disse, og anvendelse som medikamenter | |
ATE541855T1 (de) | Weitere kristalline formen von rostafuroxin |